Zacks: Brokerages Anticipate Sierra Oncology Inc (NASDAQ:SRRA) Will Post Earnings of -$0.22 Per Share
Wall Street brokerages expect Sierra Oncology Inc (NASDAQ:SRRA) to announce earnings per share of ($0.22) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.23). Sierra Oncology posted earnings of ($0.21) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 4.8%. The firm is scheduled to issue its next earnings report on Thursday, November 14th.
On average, analysts expect that Sierra Oncology will report full-year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.76). For the next financial year, analysts anticipate that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($0.91) to ($0.75). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20).
NASDAQ:SRRA remained flat at $$0.43 during mid-day trading on Monday. The company’s stock had a trading volume of 184,600 shares, compared to its average volume of 406,235. Sierra Oncology has a 1 year low of $0.40 and a 1 year high of $2.07. The company has a fifty day moving average price of $0.53 and a two-hundred day moving average price of $1.20. The company has a current ratio of 9.24, a quick ratio of 13.07 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $32.85 million, a price-to-earnings ratio of -0.57 and a beta of 1.24.
A number of hedge funds have recently bought and sold shares of the business. Brookstone Capital Management bought a new position in Sierra Oncology in the first quarter valued at approximately $28,000. Virtu Financial LLC bought a new position in Sierra Oncology in the first quarter valued at approximately $32,000. JPMorgan Chase & Co. grew its stake in Sierra Oncology by 981.2% in the second quarter. JPMorgan Chase & Co. now owns 43,703 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 39,661 shares in the last quarter. Acadian Asset Management LLC grew its stake in Sierra Oncology by 19.5% in the first quarter. Acadian Asset Management LLC now owns 486,493 shares of the biotechnology company’s stock valued at $831,000 after purchasing an additional 79,388 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Sierra Oncology by 22.0% in the second quarter. Renaissance Technologies LLC now owns 2,312,634 shares of the biotechnology company’s stock valued at $1,295,000 after purchasing an additional 417,300 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Recommended Story: Do equity income investments outperform growth and income investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.